» Articles » PMID: 18945331

Pathophysiology and Management of Fluid and Electrolyte Disturbances in Patients on Chronic Dialysis with Severe Hyperglycemia

Overview
Journal Semin Dial
Specialty Nephrology
Date 2008 Oct 24
PMID 18945331
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

The mechanisms of fluid and solute abnormalities that should be considered in any patient with severe hyperglycemia include changes in the total amount of extracellular solute, osmotic diuresis, intake of water driven by thirst, and influences from associated conditions. The absence of osmotic diuresis distinguishes dialysis-associated hyperglycemia (DH) from hyperglycemia with preserved renal function (HPRF). Mainly because of this absence, comparable degrees of hyperglycemia tend to produce less hypertonicity and less severe intracellular volume contraction in DH than in HPRF, while extracellular volume is expanded in DH but contracted in HPRF. Ketoacidosis can develop in both DH and HPRF. Among DH patients, hyperkalemia appears to be more frequent when ketoacidosis is present than when nonketotic hyperglycemia is present. Among HPRF patients, the frequency of hyperkalemia appears to be similar whether ketoacidosis or nonketotic hyperglycemia is present. Usually patients with severe DH have no symptoms or may exhibit a thirst. Infrequent clinical manifestations of DH include coma and seizures from hypertonicity or ketoacidosis and pulmonary edema from extracellular expansion. Insulin infusion is usually the only treatment required to correct the biochemical abnormalities and reverse the clinical manifestations of DH. Monitoring of the clinical manifestations and biochemical parameters during treatment of DH with insulin is needed to determine whether additional measures, such as administration of saline, free water, or potassium salts, as well as emergency hemodialysis (HD) are needed. Emergency HD carries the risk of excessively rapid decline in tonicity; its benefits in the treatment of DH have not been established.

Citing Articles

The Effect of a Subsequent Dose of Dexmedetomidine or Other Sedatives following an Initial Dose of Dexmedetomidine on Electrolytes, Acid-Base Balance, Creatinine, Glucose, and Cardiac Troponin I in Cats: Part II.

Margeti C, Kazakos G, Galatos A, Skampardonis V, Zacharopoulou T, Tsioli V Vet Sci. 2024; 11(4).

PMID: 38668411 PMC: 11053990. DOI: 10.3390/vetsci11040143.


Hypernatremia in Hyperglycemia: Clinical Features and Relationship to Fractional Changes in Body Water and Monovalent Cations during Its Development.

Wagner B, Ing T, Roumelioti M, Sam R, Argyropoulos C, Lew S J Clin Med. 2024; 13(7).

PMID: 38610721 PMC: 11012913. DOI: 10.3390/jcm13071957.


and -A Comparison of Antioxidant and Immunomodulatory Activities of Standardized Fruit Extracts in Human Neutrophils and Caco-2 Models.

Czerwinska M, Bobinska A, Cichocka K, Buchholz T, Wolinski K, Melzig M Plants (Basel). 2021; 10(11).

PMID: 34834710 PMC: 8618406. DOI: 10.3390/plants10112347.


Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus.

Liu D, Bai J, Yao J, Wang Y, Chen T, Xing Q Diabetes Metab Syndr Obes. 2021; 14:1909-1917.

PMID: 33953588 PMC: 8092849. DOI: 10.2147/DMSO.S302627.


Biochemical Parameters of Diabetes Ketoacidosis in Patients with End-stage Kidney Disease and Preserved Renal Function.

Galindo R, Pasquel F, Vellanki P, Zambrano C, Albury B, Perez-Guzman C J Clin Endocrinol Metab. 2021; 106(7):e2673-e2679.

PMID: 33659978 PMC: 8502445. DOI: 10.1210/clinem/dgab126.